Delhi's elderly face pneumonia risk as vaccination gap widens ahead of winter

Every winter, Delhi's hospitals fill with elderly patients struggling to breathe. The pattern is predictable: cold air settles over the city, pollution thickens, a viral infection takes hold, and for someone over sixty with diabetes or heart disease, that infection becomes bacterial pneumonia. A hospital stay costs fifty thousand rupees. Intensive care doubles that. For a pensioner or daily-wage worker, one illness can erase months of income and push a family below the line they've worked to stay above.

This suffering is preventable. A vaccine exists. Infants in India receive it routinely—eighty-three percent of them, according to World Health Organization data from 2023. The vaccine, pneumococcal conjugate, was added to India's free immunization program for children in 2017 and has saved countless young lives. But the grandparents of those vaccinated children are almost entirely unprotected. National survey data shows that only four-tenths of one percent of Indians aged sixty and older have received pneumococcal vaccination. While one generation sleeps safely under a public health umbrella, the other is left to navigate a private market they cannot afford.

Delhi's winter makes this gap deadly. In December 2025, the city experienced its most toxic month in six years, with an average Air Quality Index of 351. Cold air traps particulate matter near the ground; prolonged exposure weakens the lungs' natural defenses. Between 2022 and 2024, six Delhi government hospitals alone recorded more than two hundred thousand cases of acute respiratory illness and thirty thousand hospital admissions. When pollution spiked throughout December 2025, doctors reported a twenty to thirty percent surge in respiratory patients, including people who had never experienced such conditions before. These figures capture only a fraction of the true burden—they exclude private clinics, self-medication, unconfirmed infections, and cases recorded under different diagnoses.

India's 2026 consensus guidelines on adult immunization recommend pneumococcal vaccination for all adults over fifty, and for younger adults with chronic conditions. The medical evidence is clear. Yet India has no National Adult Immunisation Policy. Vaccination rates depend entirely on individual awareness, access to a doctor, and ability to pay out of pocket—a system that systematically excludes older people in lower-income families. The Longitudinal Ageing Study in India found that only around six-tenths of one percent of people over forty-five had received the vaccine, a figure that has barely moved in years.

The death toll is substantial but largely invisible. India recorded 35,987 pneumonia deaths in 2024, making it the leading cause of respiratory death. That figure understates the true number, since the certification system covers only one-fifth to one-quarter of all registered deaths nationally, and elderly people who die at home are almost never counted. Year after year, Delhi's data shows the same pattern: pneumonia deaths concentrated among the group for whom a vaccine is available but for whom no public system provides it.

The solution is concrete and affordable. Delhi could provide free pneumococcal vaccination to adults aged sixty and older with recorded chronic conditions through its existing network of dispensaries and neighborhood clinics. A single dose costs a few thousand rupees—a fraction of the sixty-five thousand rupees a hospitalization episode costs. The city already vaccinates its grandchildren. The medical case for vaccinating the grandparents is identical; it is merely administratively absent. Before winter arrives this year, that gap could close.